Crucell to Concentrate Research and Development in Leiden, The Netherlands
Leiden, The Netherlands, October 30, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it will concentrate its research and development (R&D) activities at its Leiden headquarters in The Netherlands. Vaccine manufacturing, regulatory activities, clinical development and vaccine marketing will be concentrated in Crucell’s Swiss operations in Bern.
The decision to concentrate R&D in Leiden has been made to increase efficiency in R&D spending and will result in a reduction in the number of staff employed. Due to the suspension in July 2006 of Aerugen®, the vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, there are fewer projects requiring development support at Bern. This restructuring will result in the reduction of approximately 60 positions, mainly in Bern.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled “Risk Factors”. The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
- Contact Information
- Paul Vermeij
- Director Investor Relations and Corporate Communications
- Crucell N.V.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.